Article citationsMore>>
Saxena, V., Nyberg, L., Pauly, M., Dasgupta, A., Nyberg, A., Piasecki, B., Winston, B., Redd, J., Ready, J. and Terrault, N. (2015) Safety and Efficacy of Simeprevir/Sofosbuvir in Hepatitis C Infected Patients with Compensated and Decompensated Cirrhosis. Hepatology, 62, 715-725.
https://doi.org/10.1002/hep.27922
has been cited by the following article:
-
TITLE:
Value of Child-Turcotte-Pugh Score in Prediction of Treatment Response in “Difficult to Treat” Chronic HCV Cirrhotic Patients
AUTHORS:
Taghrid Mohamed Abdalla, Sameh M. Abdel Monem, Hosam M. Dawod
KEYWORDS:
Hepatitis C, Child Score, Cirrhosis
JOURNAL NAME:
Open Journal of Gastroenterology,
Vol.9 No.11,
November
21,
2019
ABSTRACT: Background and aim: The direct-acting antivirals (DAAs) treatment has greatly improved sustained virologic response (SVR) in chronic non-cirrhotic hepatitis C virus (HCV) patients and to less extent in those with cirrhosis. There is a stressing need for predicting the outcome of DAAs treatment especially in “difficult to treat” patients. This work aimed to study the value of the Child-Turcotte-Pugh (CTP) score in the prediction of treatment outcome with DAAs in “difficult to treat” chronic HCV patients. Materials and methods: A retrospective cohort study was conducted where files of 120 “difficult to treat” patients were randomly selected from the follow-up clinic. Patients’ data were collected before and after treatment including history taking, clinical examination, laboratory investigations, and abdominal ultrasonography. Child-Turcotte-Pugh (CTP) scores were calculated. Results: There was no significant difference in mean Child score between patients with and without SVR before treatment, while this difference became significant after treatment. The patients without complications showed a highly significant decrease in their mean Child score after treatment, while patients with complications did not show any significant differences. Conclusion: The baseline Child-Turcotte-Pugh score cannot predict the treatment response of DAAs in “difficult to treat” chronic HCV patients, but it is significantly associated with the occurrence of complications.
Related Articles:
-
Mariam M. Mirambo, Benson R. Kidenya, Vitus Silago, Emmanuel Mkumbo, Awadh Mujuni, Kennedy J. Mmanga, Japhet J. Mwihambi, Shimba Henerico, Carolyne A. Minja, Stephen E. Mshana
-
Ali A. Ghweil, Heba A. Osman, Ashraf Khodeary
-
A. Hanno, D. Elwazzan, M. Ibrahim, R. Hafez
-
Doffou Adjeka Stanislas, Assi Constant, Ndjitoyap Ndam Antonin Wilson, Kouame Hardryt Dimitri, Bangoura Demba, Kissi Anzouan-Kacou, Ouattara Amadou, Lohoues-Kouacou Marie-Jeanne, Attia Koffi Alain
-
Boua-Akelelo Nathalie Philomène, Youssouf Oumarou, Gambo Ignaleamoko Nuella Edwige, Yangba Kalebanga Armel, Elowa Jean Benoît, Kobelembi Mofini E, Bessanguem Bernard, Komaria Hermann, Service George, Kobelembi Armand, Camengo Police Serge Magloire